Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and Older

Authors not listed

Guangzhou Patronus Biotech Co., Ltd. · 2024

Dysbiosis Human Randomized controlled trial

Abstract

A phase 1, randomized, observer-blinded, parallel-controlled, dose escalation study in Australia will evaluate the safety and immunogenicity of the RSV vaccine candidate LYB005 with or without adjuvant in healthy adults aged 18 years and older.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-11-06 MST

Cite this

APA

Anonymous. (2024). A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and Older. <em>Guangzhou Patronus Biotech Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT06442241

Vancouver

Anonymous. A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and Older. Guangzhou Patronus Biotech Co., Ltd.. 2024.

BibTeX

@misc{anon2024APhase, title = {A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and Older}, author = {Anonymous}, journal = {Guangzhou Patronus Biotech Co., Ltd.}, year = {2024}, }